A natural sugar delivers DNA aptamer drug inside tumor cells

©2014, Mary Ann Liebert, Inc., publishers

Drugs comprised of single strands of DNA, called aptamers, can bind to targets inside tumor cells causing cell death. But these DNA drugs cannot readily get inside tumor cells on their own. Effective delivery of DNA aptamers using a natural polysaccharide as a carrier is described in an article in Nucleic Acid Therapeutics.

Tatyana Zamay and coauthors, Krasnoyarsk State Medical University, Siberian Branch Russian Academy of Sciences, and Center for Reproductive Medicine (Krasnoyarsk, Russia), and University of Ottawa, Canada, combined the arabinogalactan, obtained from the larch tree, with a DNA drug that binds to and disrupts the activity of vimentin, a structural protein required for cell division. Vimentin is often over-produced by compared to normal cells.

In the article "DNA-Aptamer Targeting Vimentin for Tumor Therapy in Vivo" the authors show that an aptamer targeting vimentin inhibits tumor growth more effectively when it is administered as a mixture with arabinogalactan than alone.

"This work demonstrates the advancement of aptamer therapeutic application through increased bioavailability using a nontoxic polysaccharide based therapy," says Executive Editor Graham C. Parker, PhD.

add to favorites email to friend print save as pdf

Related Stories

New DNA and RNA aptamers offer unique therapeutic advantages

Aug 05, 2009

A novel class of drugs composed of single strands of DNA or RNA, called aptamers, can bind protein targets with a high strength and specificity and are currently in clinical development as treatments for a broad range of ...

A tighter fit with artificial DNA

Jul 19, 2013

An artificial base that enhances the protein-binding affinity and selectivity of DNA expands the DNA machinery.DNA aptamers are expected to play an important role in the diagnosis and treatment of various ...

Recommended for you

70-gene signature not cost-effective in breast cancer

Oct 18, 2014

(HealthDay)—For patients with node-negative breast cancer (NNBC), the 70-gene signature is unlikely to be cost-effective for guiding adjuvant chemotherapy decision making, according to a study published ...

User comments